Maternal serum visfatin at 11–13 weeks’ gestation in preeclampsia

Ferreira, Ana Fatima A.; Rezende, Juliana Costa de; Oliveira, Raqueli de; Akolekar, Ranjit; Nicolaides, Kypros H.

doi:10.1038/jhh.2012.10

Cited by 18 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathogenesis of pregnancy-associated hypertensive disorders involves complex immunopathogenic mechanisms and it is highly likely that the observed associations of visfatin in PE might be due to these immunological mechanisms rather than simple metabolic effects. This is also supported by the study by Ferreira et al ( 2013) who report serum visfatin levels at 11-13 weeks to be increased in women who develop PE. These authors suggest that such an increase might be mediated by a mechanism unrelated to impaired placental perfusion.…”

Section: Pre-eclampsiasupporting

confidence: 66%

The role of visfatin (PBEF/Nampt) in pregnancy complications

Pavlová

Novák

Bienertová-Vašků

2015

Journal of Reproductive Immunology

View full text Add to dashboard Cite

Section: Pre-eclampsiasupporting

confidence: 66%

The role of visfatin (PBEF/Nampt) in pregnancy complications

Pavlová

Novák

Bienertová-Vašků

2015

Journal of Reproductive Immunology

View full text Add to dashboard Cite

“…4,17,18 In contrast to our findings, Wensheng et al, which reported a decrease in serum Visfatin level in preeclamptic pregnant women compared to control. …”

Section: Discussioncontrasting

confidence: 99%

Relation of serum visfatin level and uterine artery Doppler to preeclampsia

El-Samra

Aggag²

2017

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

INTRODUCTIONPreeclampsia is an important cause of fetomaternal morbidity and mortality. It is not only unpredictable in onset and progression, but also has no effective management strategy except termination of pregnancy. 1,2Despite the intensive efforts to delineate the pathophysiology of preeclampsia, neither a specific cause nor pathogenesis has been identified. 3One of the contributing factors which can play a role in the pathophysiology of preeclampsia is alteration in the ABSTRACT Background: Preeclampsia (PE) is a significant cause of remarkable fetomaternal morbidity and mortality worldwide. Visfatin is 52 KDa novel adipokine, pre B cell colony enhancing factor (PBEF) which could be used as a biochemical marker predictor or a diagnostic tool for preeclampsia. Trans abdominal pulsed Doppler ultrasound (US) monitor the impedance to blood flow in the uterine arteries in pregnant females and those with preeclampsia. Visfatin has been implicated in the pathogenesis of preeclampsia with a limited contradictory. The aim of our study is to monitor the risky pregnant females through Visfatin level and transabdominal pulsed Doppler of the uterine artery. Methods: Assessment of the serum Visfatin levels in the maternal circulation of preeclamptic pregnant females wether mild or severe, and compared to those in the normal pregnant subjects as control through recruitment of cases of mild PE (n=40), severe PE (n=40), normal pregnant subjects (n=60) in a cross sectional study where the cases were of the patients hospitalized at El Shatby Hospital of Obstetrics and Gynecology, and the control subjects were of referrals to the outpatient departments. Fasting blood samples were drawn, kept at -20 degree centigrades , enzyme linked immune sorbant assay (ELISA) Test was performed on them to determine the Visfatin level and recorded the uterine arteries pulsatility index through transabdominal doppler ultrasound. Lastly, the data were analysed using (F test) ANOVA statistical method. Results: Amongst the groups, Serum visfatin level was significantly higher in the severe preeclamptic group rather than the normal pregnant group and those with mild preeclampsia (p<0.001). Uterine artery pulsatility index was significantly higher in the severe preeclamptic group rather than the normal pregnant group and those with mild preeclampsia (p<0.001). Conclusions: Severe preeclamptic pregnant females were shown to represent higher circulating visfatin levels as one of the most recent biochemical markers of preeclampsia, higher uterine artery pulsatility index compared to normal pregnant and those with mild preeclamptic groups of women.

show abstract

“…Most studies provide evidence for increased plasma visfatin levels in PE as compared with normotensive pregnant 16,20 or increased serum visfatin levels in PE 17,19 and in the 11-13th weeks of pregnancy in women who developed PE. 18 Conversely, other studies showed decreased serum visfatin levels in PE 21 or decreased visfatin expression in the placental bed in PE as compared with normotensive controls. 22 However, we found no significant differences in plasma visfatin/NAMPT levels when we compared the HP, GH and PE groups.…”

Section: Discussionmentioning

confidence: 93%

“…14 Previous studies reviewed the contribution of visfatin/NAMPT in PE. 15 Most findings provide evidence for increased circulating visfatin levels [16][17][18][19][20] in patients with PE, although decreased serum visfatin levels 21 or visfatin expression have also been reported in PE. 22 Moreover, other studies found no differences in circulating visfatin levels when normal pregnant were compared with patients with PE.…”

Section: Introductionmentioning

confidence: 99%

Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy

et al. 2015

View full text Add to dashboard Cite

Dysregulation of adipocytokines may be associated with endothelial dysfunction in women with preeclampsia (PE), who are at increased risk of future cardiovascular disease. Visfatin, an adipocytokine with a potential cardiovascular role, is also known as nicotinamide phosphorybosil transferase (NAMPT). NAMPT gene polymorphisms affect circulating visfatin/NAMPT levels in obesity. Most findings provide evidence for increased visfatin/NAMPT circulating levels in PE. However, no previous study has tested the hypothesis that NAMPT polymorphisms affect visfatin/NAMPT levels in hypertensive disorders of pregnancy. We studied the effects of the NAMPT polymorphisms T>C (rs1319501) and A>G (rs3801266), and the haplotypes formed by them on visfatin/NAMPT levels and whether these genetic markers are associated with gestational hypertension (GH) and PE. We studied 212 healthy pregnant (HP), 181 patients with GH and 208 with PE. Genotypes were determined by Taqman allele discrimination assays. Plasma visfatin/NAMPT levels were measured by ELISA. No significant differences in visfatin/NAMPT levels were found among the groups. However, higher visfatin/NAMPT levels (P<0.05) were found in GH patients carrying the AG or the GG genotypes for the rs3801266 polymorphism or the 'T, G' haplotype. The TC and CC genotypes and the C allele for the rs1319501 polymorphism were more frequent in the HP than in the PE group (P<0.05). Moreover, the 'C, A' haplotype was also more frequent in the HP than in the PE group (P<0.01). Our findings suggest that although the rs3801266 polymorphism and the 'T, G' haplotype affect visfatin/NAMPT levels in GH, the rs1319501 polymorphism and the 'C, A' haplotype affect the susceptibility to PE.

show abstract

Maternal serum visfatin at 11–13 weeks’ gestation in preeclampsia

Cited by 18 publications

References 41 publications

The role of visfatin (PBEF/Nampt) in pregnancy complications

The role of visfatin (PBEF/Nampt) in pregnancy complications

Relation of serum visfatin level and uterine artery Doppler to preeclampsia

Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy

Contact Info

Product

Resources

About